Celgene (CELG) announces the presentation of two studies evaluating a Revlimid/ rituximab combo...

|About: Celgene Corporation (CELG)|By:, SA News Editor

Celgene (CELG) announces the presentation of two studies evaluating a Revlimid/ rituximab combo in non-Hodgkins lymphomas. The company's executive vice president for Hematology and Oncology says "The increasing volume of clinical evidence evaluating [these] combinations … provide us powerful insight into the potential of antibody-dependent cellular cytotoxicity in lymphomas." (PR)